

NEW CLAIMS

1. A pharmaceutical product for the treatment of viral infections, in particular of the human immunodeficiency virus (HIV), characterized in that the pharmaceutical product comprises a compound that as active component contains an iron chelator and a component comprising another virus-inhibiting compound.

2. A pharmaceutical product according to claim 1, characterized in that the iron chelator is selected from the group of hydroxamates (such as deferoxamine), the family of the hydroxypyridinons (such as deferiprone), and the nucleic acid-binding chemotherapeutical products (such as bleomycine).

3. A pharmaceutical product according to claim 2, characterized in that the virus-inhibiting compound is a protease-inhibitor.

4. A pharmaceutical product according to claim 3, characterized in that the protease-inhibitor is ritonavir.

5. A pharmaceutical product according to claim 1, characterized in that the virus-inhibiting compound is a reverse transcriptase inhibitor.

6. A pharmaceutical product according to claim 5, characterized in that the reverse transcriptase inhibitor is a dideoxyinosine.